
KYTX Stock Forecast & Price Target
KYTX Analyst Ratings
Bulls say
Kyverna Therapeutics is positioned for success in the cell therapy market with its unique KYV-101 and KYV-201 products targeting autoimmune diseases. The company has identified a sizable immediate addressable market and has already established partnerships with top academic centers. Its strong financials and potential for biologics-like margins further support a positive outlook, with upcoming catalysts in the form of a BLA submission and commercial build-out. Additionally, the promising data for its lead indication, SPS, and deepening response for gMG, highlight the potential for significant demand for its products.
Bears say
Kyverna Therapeutics is a small biopharmaceutical company with a limited pipeline and a focus on developing cell therapies for autoimmune diseases. While their recent Phase 1 data for their product candidate miv-cel in rheumatoid arthritis (RA) is positive, it only includes difficult-to-treat patients and does not fully justify the high valuation of the company. Additionally, there are risks involved in the development and approval of their product candidates, including potential lack of durable responses and long-term dilution risk, which could negatively impact the company's stock in the future.
This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KYTX Analyst Forecast & Price Prediction
Start investing in KYTX
Order type
Buy in
Order amount
Est. shares
0 shares